HomeBUSINESS
BUSINESS

Pfizer Begins Submitting Applications for Biosimilars, Could Be First Major New Drug Maker to Enter Japanese Market
(Nov.21.2017)

Pfizer Japan has begun submitting applications for domestic marketing authorization for a number of biosimilars. The first was for a biosimilar of the anti-rheumatoid arthritis (RA) drug Remicade (infliximab). Four other biosimilars are in PIII clinical development and could be submitted for approval in the near future. If these products are approved, Pfizer will be the first major original drug maker to enter the Japanese biosimilar market on a full scale ...
(LOG IN FOR FULL STORY)